Download Poster (277.87 KB)

Symposium

APLAR •
5 September, 2025 •
•

Management of MAS and Still’s Disease: Challenges and opportunities

Masaki Shimizu, Fabrizio De Benedetti

Available materials

Slides Video

Publication

ACR •
28 October, 2025 •
•

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Publication

ACR •
27 October, 2025 •
•

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Publication

ACR •
26 October, 2025 •
•

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Publication

Efficacy and Safety of Emapalumab for Treating Macrophage Activation Syndrome in Still’s disease: A Pooled Analysis of Two Prospective Trials

Management of MAS and Still’s Disease: Challenges and opportunities

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Changes in Pharmacodynamic Markers (PD) in Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials